304 related articles for article (PubMed ID: 32147909)
1. Analysis of DNA methylation patterns in the tumor immune microenvironment of metastatic melanoma.
Mitra S; Lauss M; Cabrita R; Choi J; Zhang T; Isaksson K; Olsson H; Ingvar C; Carneiro A; Staaf J; Ringnér M; Nielsen K; Brown KM; Jönsson G
Mol Oncol; 2020 May; 14(5):933-950. PubMed ID: 32147909
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylation sequencing of paired primary and metastatic cell lines identifies common DNA methylation changes and a role for EBF3 as a candidate epigenetic driver of melanoma metastasis.
Chatterjee A; Stockwell PA; Ahn A; Rodger EJ; Leichter AL; Eccles MR
Oncotarget; 2017 Jan; 8(4):6085-6101. PubMed ID: 28030832
[TBL] [Abstract][Full Text] [Related]
3. Promoter Methylation of PTEN Is a Significant Prognostic Factor in Melanoma Survival.
Roh MR; Gupta S; Park KH; Chung KY; Lauss M; Flaherty KT; Jönsson G; Rha SY; Tsao H
J Invest Dermatol; 2016 May; 136(5):1002-1011. PubMed ID: 26854490
[TBL] [Abstract][Full Text] [Related]
4. Data mining of immune-related prognostic genes in metastatic melanoma microenvironment.
Han W; Huang B; Zhao XY; Shen GL
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33169786
[TBL] [Abstract][Full Text] [Related]
5. BRN2 is a non-canonical melanoma tumor-suppressor.
Hamm M; Sohier P; Petit V; Raymond JH; Delmas V; Le Coz M; Gesbert F; Kenny C; Aktary Z; Pouteaux M; Rambow F; Sarasin A; Charoenchon N; Bellacosa A; Sanchez-Del-Campo L; Mosteo L; Lauss M; Meijer D; Steingrimsson E; Jönsson GB; Cornell RA; Davidson I; Goding CR; Larue L
Nat Commun; 2021 Jun; 12(1):3707. PubMed ID: 34140478
[TBL] [Abstract][Full Text] [Related]
6. Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology.
Failmezger H; Muralidhar S; Rullan A; de Andrea CE; Sahai E; Yuan Y
Cancer Res; 2020 Mar; 80(5):1199-1209. PubMed ID: 31874858
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
8. A novel hypoxia-associated subset of FN1 high MITF low melanoma cells: identification, characterization, and prognostic value.
Wouters J; Stas M; Govaere O; Barrette K; Dudek A; Vankelecom H; Haydu LE; Thompson JF; Scolyer RA; van den Oord JJ
Mod Pathol; 2014 Aug; 27(8):1088-100. PubMed ID: 24390218
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
Basu B; Chakraborty J; Chandra A; Katarkar A; Baldevbhai JRK; Dhar Chowdhury D; Ray JG; Chaudhuri K; Chatterjee R
Clin Epigenetics; 2017; 9():13. PubMed ID: 28174608
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
11. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin.
Lahtz C; Stranzenbach R; Fiedler E; Helmbold P; Dammann RH
J Invest Dermatol; 2010 Feb; 130(2):620-2. PubMed ID: 19798057
[No Abstract] [Full Text] [Related]
12. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
13. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients.
Seremet T; Koch A; Jansen Y; Schreuer M; Wilgenhof S; Del Marmol V; Liènard D; Thielemans K; Schats K; Kockx M; Van Criekinge W; Coulie PG; De Meyer T; van Baren N; Neyns B
J Transl Med; 2016 Aug; 14(1):232. PubMed ID: 27484791
[TBL] [Abstract][Full Text] [Related]
14. DNA hypermethylation is associated with invasive phenotype of malignant melanoma.
Koroknai V; Szász I; Hernandez-Vargas H; Fernandez-Jimenez N; Cuenin C; Herceg Z; Vízkeleti L; Ádány R; Ecsedi S; Balázs M
Exp Dermatol; 2020 Jan; 29(1):39-50. PubMed ID: 31602702
[TBL] [Abstract][Full Text] [Related]
15. Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation.
Lauss M; Haq R; Cirenajwis H; Phung B; Harbst K; Staaf J; Rosengren F; Holm K; Aine M; Jirström K; Borg Å; Busch C; Geisler J; Lønning PE; Ringnér M; Howlin J; Fisher DE; Jönsson G
J Invest Dermatol; 2015 Jul; 135(7):1820-1828. PubMed ID: 25705847
[TBL] [Abstract][Full Text] [Related]
16. Aberrant DNA methylation is associated with aggressive clinicopathological features and poor survival in cutaneous melanoma.
de Unamuno Bustos B; Murria Estal R; Pérez Simó G; Simarro Farinos J; Pujol Marco C; Navarro Mira M; Alegre de Miquel V; Ballester Sánchez R; Sabater Marco V; Llavador Ros M; Palanca Suela S; Botella Estrada R
Br J Dermatol; 2018 Aug; 179(2):394-404. PubMed ID: 29278418
[TBL] [Abstract][Full Text] [Related]
17. High-frequency p16(INK) (4A) promoter methylation is associated with histone methyltransferase SETDB1 expression in sporadic cutaneous melanoma.
Kostaki M; Manona AD; Stavraka I; Korkolopoulou P; Levidou G; Trigka EA; Christofidou E; Champsas G; Stratigos AJ; Katsambas A; Papadopoulos O; Piperi C; Papavassiliou AG
Exp Dermatol; 2014 May; 23(5):332-8. PubMed ID: 24673285
[TBL] [Abstract][Full Text] [Related]
18. Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis.
Marzese DM; Scolyer RA; Huynh JL; Huang SK; Hirose H; Chong KK; Kiyohara E; Wang J; Kawas NP; Donovan NC; Hata K; Wilmott JS; Murali R; Buckland ME; Shivalingam B; Thompson JF; Morton DL; Kelly DF; Hoon DS
Hum Mol Genet; 2014 Jan; 23(1):226-38. PubMed ID: 24014427
[TBL] [Abstract][Full Text] [Related]
19. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma.
Erdag G; Schaefer JT; Smolkin ME; Deacon DH; Shea SM; Dengel LT; Patterson JW; Slingluff CL
Cancer Res; 2012 Mar; 72(5):1070-80. PubMed ID: 22266112
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma.
Venza M; Visalli M; Catalano T; Biondo C; Beninati C; Teti D; Venza I
Oncol Rep; 2016 Apr; 35(4):2451-60. PubMed ID: 26883095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
